Dr. Wagner on the Value of Cooperative Research Groups in Angiosarcoma


Michael J. Wagner, MD, discusses the importance of cooperative research groups in angiocarcinoma.

Michael J. Wagner, MD, assistant professor, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, discusses the importance of cooperative research groups in angiocarcinoma.

Angiosarcoma is a rare subset of an already rare disease, soft tissue sarcomas. Due to the lack of patients, it can be difficult for single institutions to recruit enough participants to conduct clinical trials.

Clinical trials requires collaboration, according to Wagner, who calls cooperative groups like EGOC, the Alliance, and SWOG "critical" for conducting research. Findings from the Angiosarcoma Project discovered the connection between exposure to ultraviolet light and angiosarcoma.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD